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ABSTRACT: Antigen recognition by antibodies plays an
important role in human biology and in the development of
diseases. This interaction provides a basis for multiple
diagnostic assays and is a guide for treatments. We have
developed dihydropyridine-based ﬂuorophores that form
stable complexes with double-stranded DNA and upon
recognition of the antibodies to DNA (anti-DNA) provide
an optical response. The ﬂuorophores described herein have
advantageous optical properties compared to those of the currently available dyes making them valuable for research and clinical
diagnostics. By studying a series of novel ﬂuorophores, crucial parameters for the design were established, providing the
required sensitivity and speciﬁcity in the detection of antibodies. Using these DNA−ﬂuorophore complexes in a direct
immunoﬂuorescence assay, antibodies to DNA are speciﬁcally detected in 80 patients diagnosed with an autoimmune disease,
systemic lupus erythematosus. Positivity indicated by emission change of α-(4′-O-methoxyphenyl)-2-furyl dihydropyridine
strongly correlates with other disease biomarkers and autoimmune arthritis.
1. INTRODUCTION
Antibodies are proteins of key importance that provide defense
against cancer, bacteria, and viruses.1 However, in autoimmune
diseases, antibodies attack one’s own cells and tissues.2 To
prevent the disease development, autoimmune antibodies have
to be diagnosed early and a treatment has to be started.
Among others, antibodies to nuclear components of cells
(antinuclear antibodies) and to double-stranded DNA
(dsDNA) are distinctive biomarkers of systemic lupus
erythematosus (SLE), a chronic autoimmune disease with
multiple manifestations, and life-threatening damage to human
organism.3,4 Recent studies point at the broad range of
autoimmune conditions that involve highly reactive anti-
double-stranded DNA (a-dsDNA) antibodies as well.5
Detection of antibodies is currently performed either by
indirect immunoassays or by direct detection methods.6 The
indirect methods are usually carried out by variants of the
enzyme-linked immunosorbent assay (ELISA) and are widely
used.7 Direct detection can be done by ﬂuorescence
microscopy, surface plasmon resonance, or ﬂuorometry.8−10
ELISA is highly sensitive but time demanding and rather
costly. The direct methods are simpler in handling, more
accurate in target quantiﬁcation, and inexpensive compared
with ELISA.8−10
The key to successful detection of any antibody is a properly
designed and highly pure antigen.10 Synthetic oligonucleotides
represent an emerging class of antigens for the detection and
study of autoimmune antibodies. We and others recently
proved the utility of rationally designed dsDNA molecules in
the diagnostics of SLE.10−12 Using these antigens and the
commercially available dye Eva green, we were able to detect
the antibody−DNA interaction by a simple ﬂuorometry assay
(Figure 1).10 Several studies addressed the issue of the DNA
sequence recognition by the antibodies.10−14 Nevertheless,
new dyes with improved properties for the direct immuno-
ﬂuorescence are on demand. In particular, high optical
sensitivity to DNA and antibodies would be advantageous to
increase speciﬁcity of the assay.
DNA origami is an exciting research and diagnostic tool that
allows for sensitive detection of a broad range of targets.15
Origami can be folded into the various shapes, ranging from a
nanobox to ﬂat sheet, by adding a set of synthetic
oligonucleotide primers to the large viral DNA strand.15
Reaching a size of 100 nm, DNA origami has a plethora of
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binding sites for ﬂuorophores, small drugs, and biomolecules,
being hence an excellent tool to enhance the recognition and
detection eﬃcacy per sample volume.15 Speciﬁcally, a complex
of DNA origami with noncovalent DNA binding dye can be
used as an antigen for the detection of anti-DNA antibodies in
bioﬂuids (Figure 1a). Upon the antibody binding, a
ﬂuorophore molecules get released from the DNA origami,
providing a simple ﬂuorescence read out for the assay.16
We aimed at developing novel ﬂuorophores with advanta-
geous properties in the direct detection of human antibodies.
To address this, we designed, synthesized, and tested novel
derivatives of dihydropyridine (DHP; Figure 1b). DHP is a
parent of a class of molecules that eﬀectively recognizes
proteins.17 In particular, DHPs are well known in pharmacol-
ogy as L-type calcium channel blockers, used in the treatment
of hypertension. Our rationale for choosing the DHP scaﬀold
is that the ﬁne tuning of the substitution pattern allows for the
optimization of the DNA/protein recognition and of its optical
properties. DHP analogues were additionally decorated with
planar aromatic moieties and hydrophilic substituents that can
provide stacking interactions and hydrogen bonds with large
DNA origami.10,16 In this article, we describe the design and
synthesis of these new ﬂuorophores and prove their ability to
speciﬁcally detect human antibodies to DNA in blood samples.
Figure 1. (a) General principle of the immunoﬂuorescence assay; (b) commercially available DNA binding dyes and novel ﬂuorophores used in
this work. Eva green (1), thiazole orange (2), and novel dihydropyridines (DHPs 3−8).
Scheme 1. Synthesis of Dihydropyridines 3−8a
aR1 = 2-furyl (3, 15), 2-naphthyl (4, 16), styryl (5, 17), α-Br-2-furyl (6, 18), α-Ph-2-furyl (7, 12), and α-(4′-O-methoxyphenyl)-2-furyl (8, 13). R2
= H or Me. IPA = isopropyl alcohol.
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2. RESULTS AND DISCUSSION
Optical sensitivity of organic molecules to their microenviron-
ment is a fundament of multiple tests. However, several
biological phenomena require a ﬁne tuning of the sensor’s
optical properties. A particularly challenging task is to develop
a ﬂuorophore that allows for a sensitive and speciﬁc detection
by interaction with antigen and antibodies. Commercially
available ﬂuorophores are developed to eﬀectively recognize
either DNA or proteins, but none allow us to monitor the
switch in recognition of these two biomolecules.
In this study, our goal was to develop a ﬂuorescent molecule
that would allow us to form a bright complex with well-deﬁned
DNA origami structures able to bind and detect anti-dsDNA
antibodies. To address this, we started with a scaﬀold that is
well known to bind to proteins, dihydropyridine (DHP). By
chemical functionalization we achieved the required sensitivity
and speciﬁcity of a DHP−furan derivative and proved its
eﬃcacy in a direct immunoﬂuorescence assay.
For the ﬂuorophore design, we used available knowledge on
DNA binding by organic molecules, which combine π−π
interactions and hydrogen bonding.15,16 Furthermore, extend-
ing the aromatic system is known to increase the ﬂuorescent
quantum yield and redshift the emission wavelengths.18
Therefore, we functionalized position 4 of the DHPs (shown
in Figure 1) with several aromatic residues, potentially
inﬂuencing optical properties and biorecognition. For com-
pound 3, we introduced additional aromatic substituents at the
furan, resulting in compounds 6, 7, and 8 (Figure 1). Methyl
groups were removed in several ﬂuorophores to study the
eﬀect on DNA and antibody recognition.
Owing to their medical signiﬁcance, the synthesis of DHP
derivatives has been widely explored.19,20 A straightforward
scaﬀold diversiﬁcation was developed for the rapid preparation
of all of the designed ﬂuorophores. The synthesis of the
ﬂuorophores is shown in Scheme 1. In brief, boronic acids 9
were reacted with furfurals 11 resulting in derivatives 12−13.
Incubation of products 12−13, along with commercially
available aldehydes 15−18, with 3-aminocyclohex-2-en-1-one
(14) and 3-oxo-N-arylbutanamides (19) provided the DHPs
3−8 in up to 87% yields (see the details on synthesis and
characterization in Supporting Information, Chapter 2).
Novel ﬂuorophores were evaluated in three steps. First,
optical properties and biorecognition of each ﬂuorophore were
investigated. Second, the ﬂuorophores with optimal perform-
ance were screened against a panel of dsDNA probes to obtain
the brightest complex. Third, the selected ﬂuorophore−DNA
complexes were tested in a direct immunoﬂuorescence assay of
a-dsDNA in human samples.
Individual ﬂuorophores were analyzed by UV−vis spectros-
copy and ﬂuorometry. As expected, the substitution pattern
had a strong eﬀect on the optical properties of the
ﬂuorophores, for example, ﬂuorescence maximum for com-
pounds 3 vs 8 shifted from 430 to 470 nm in 100 mM
phosphate-buﬀered saline (PBS), pH 7.2 (Supporting In-
formation, Chapter 2). Quantum yields also varied dramati-
cally, with highest values for the ﬂuorophore complexes 4, 5,
and 8 (0.17−0.40). The molar extinction was similar for all of
the dyes and somewhat lower than for previously used thiazole
orange, 2 (Supporting Information, Table S1).
Figure 2. Characterization of DNA duplexes and origami upon adding the ﬂuorophores. (a) Tm study; (b) CD; (c, d) transmission electron
microscopy (TEM). (a, b) Experiments were carried out in 100 mM Tris−HCl buﬀer, pH 7.5, using 0.5 μM (Tm) or 2 μM (CD) DNA samples.
Double-stranded DNA sequence: (5′-TGT GGT AGT TGA GCG GAT GGC GTA GGC A-3′): (5′-TGC CTA CGC CAT CCG CTC AAC
TAC CAC A-3′). (c, d) TEM characterization of prism A incubated with no dye (c), and with 250 mM dye 8 added during annealing. For every
sample, two chosen representative TEM images are shown with a scale bar of 200 nm. This image gallery conﬁrms the stability of the prism A in the
presence of the dye.
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In general, all of the ﬂuorophores showed increased
ﬂuorescence in the presence of calf thymus DNA (CTD)
(Supporting Information, Figure S1). However, compounds
3−4, without DNA, showed no response to the addition of
bovine serum albumin (BSA). Remarkably, compound 3 nicely
discriminated the DNA (CTD) over a protein (BSA;
Supporting Information, Table S1). Fluorescence intensity of
compound 3 was slightly increased with CTD and quenched
by 2-fold upon addition of 1 mM BSA (Supporting
Information, Figure S1). Among all dyes, compound 4 and 8
gave highest brightness (FB) with CTD.
Although compound 3 showed good discrimination of
antibodies in SLE-positive sera vs controls, it had a relatively
weak ﬂuorescence compared to that of compounds 7 and 8
bound to DNA (Supporting Information, Table S1). More-
over, its absorbance maximum was below 380 nm, which is not
suitable for screening by a conventional plate reader.
To gain more information on the ﬂuorophore−DNA
complexes, we applied a model dsDNA, a 30-mer fragment
of the human genome. Using short dsDNA allowed us to
perform thermal denaturation (Tm) and circular dichroism
(CD) studies (Figure 2a,b). These well-established methods
reveal the stability of the DNA duplex and its structure in the
presence of diﬀerent concentrations of the ﬂuorophores.21,22
Eva green and thiazole orange were used as controls. It was
surprising that the dyes had a relatively small eﬀect on the
thermal stability of model dsDNA (change in Tm ± 1.5 °C,
with a measurement precision of ±0.5 °C). Similarly to Eva
green and thiazole orange, CD studies indicated that DHP
derivatives 3−5 had little eﬀect on the secondary structure of
dsDNA (Supporting Information, Chapter 3). A possible
interaction mode of ﬂuorophores with DNA could be an
intercalation.18 However, the observed lack of ﬂuorescence
quenching and unchanged CD and Tm proﬁles for compounds
3−5 vs DNA exclude the potential intercalation.18
To study the eﬀect of the dyes on the stability of large DNA
origami, we applied agarose gel electrophoresis and trans-
mission electron microscopy (TEM) (Supporting Information,
Figures S5,S6 and 2c,d). For these studies, we selected two
representative dyes, 3 and 8, and prism A. Agarose gel of prism
A incubated with no dye, 3, or 8 in increasing concentrations
of 50, 250, and 500 mM, revealed a faster migration of the
front band. This is evident of proper folding of the prism A in
all cases (Supporting Information, Figure S6A). TEM images
also conﬁrm a well-deﬁned structure for prism A when dyes 3
and 8 are added (see Supporting Information Figure S6E for
3−prism A TEM).
We aimed at ﬁnding the optimal DNA antigen to form a
bright and stable complex with ﬂuorophores 5 and 8. We chose
5 and 8 due to their high brightness and aﬃnity toward
dsDNA (see Supporting Information, Tables S1 and S2).
Recent studies show that large well-deﬁned three-dimensional
(3D) DNA origami structures are advantageous in terms of
brightness in the direct immunoﬂuorescence assay.10,16,23
Following this lead, we screened ﬁve previously reported
origami structures: box, platform, ring, and two prism variants
(Figure 1b).10,24−26 Annealing of origami was done as
previously described,10 and the dye of interest was added
during the thermal ramp at 65 °C (see Supporting Information
Chapter 4 for details). The resulting complexes were studied
by ﬂuorometry in PBS buﬀer (Supporting Information, Figure
S6B) and upon addition of human sera containing antibodies
to DNA (Figure 3; SLE1−2). In the absence of sera, prism A
and CTD formed bright complexes with 5, whereas 8 had the
brightest signal when bound to platform and prism A. The
discrimination of binding by ﬂuorescence was highest for 8,
reaching 4.7-fold change of intensity, compared with 2.1-fold
change showed by 5 (Supporting Information, Figure S6B).
We carried out the direct immunoﬂuorescence detection
using 1 nM prism A, with an excess of ﬂuorophore (5 or 8 at
250 nM) and 2 μL human plasma in 10 μL incubation buﬀer
(1 g BSA, 200 μL Tween-20 in 1 L 1× PBS). The samples
were incubated at 37 °C for 1.5 h and then analyzed by
ﬂuorometry, as shown in Figure 1a. Antibodies to phospholipid
cardiolipin often cross-react with dsDNA.27 Therefore, we
included anticardiolipin positive serum as a control along with
healthy patient samples (HCl and HNP, respectively). As can
be seen in Figure 3, both ﬂuorophores showed increased
ﬂuorescence in the presence of origami and CTD.
Fluorescence of the complex formed by compound 8 and
prism A decreased signiﬁcantly when adding SLE1 or SLE2
compared to that of the control sera (Supporting Information,
Figure 3. Immunoﬂuorescence screening of DNA origami vs ﬂuorophores 5 and 8. Fluorescence intensities of SLE sera and controls (human
anticardiolipin plasma, HCl, and human normal plasma, HNP), upon incubation with 5, 8, and their complexes with DNA origami prism A, calf
thymus DNA (CTD), and DNA origami box. The assay was carried out in 100 mM phosphate buﬀer (pH 7.2) containing 2% BSA, using
excitation/emission wavelengths of 360/440 nm (5) or 380/470 nm (8). Each measurement has been done in duplicates. P value is given for the
one-way analysis of variance (ANOVA) tests of all groups.
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Figure S7). However, using CTD as the DNA scaﬀold led to a
positive response in HCl. Complexes of compound 5 with all
origami structures were generally less sensitive to adding SLE
sera than those of compound 8 (Figure 3).
To evaluate the role of the 3D dsDNA structure on the
ﬂuorophore and a-dsDNA recognition, we repeated the
experiments for the origami staple strands in the absence of
the scaﬀold strand, resulting in no dsDNA origami formation
(Supporting Information, Chapter 4). In this case, the
ﬂuorescence intensity by the dyes was approximately threefold
lower than that for the assembled DNA origami structure.
Dyes 5 and 8 were also tested without DNA, in which case the
sera had no eﬀect on their ﬂuorescence properties (Supporting
Information, Figure S7B).
We studied binding kinetics and stoichiometry of prism A
with ﬂuorophores 5 and 8 by ﬂuorescence (Supporting
Information, Figures S8,S9 and Table S4).28 According to
ﬂuorescence titration studies, KD values for 5 and 8 vs prism A
were 2 and 1.1 μM, respectively, which is in the similar range
as that for previously reported DNA binding dye Eva green.29
For antibody binding, KD values for 5 and 8 were approx. 50-
fold lower than that for prism A, 40 and 26 nM, respectively
(Supporting Information, Table S4).
When the complexes of 5 and 8 with prism A were subjected
to interaction with monoclonal anti-dsDNA antibody,10 KD
values were also within the expected low nanomolar range,
1.25 and 0.24 nM for 5−prism A and 8−prism A, respectively
(Supporting Information, Table S4).30 For the negative control
(monoclonal antibody to β2-microglobulin10), no binding was
observed conﬁrming the speciﬁcity of the DNA antigens
toward anti-dsDNA antibody (Supporting Information, Figure
S10).
Binding stoichiometry was studied by binding isotherms
following the described protocol.28 For 5 and 8, the binding
ratio of prism A was estimated as 300 mole equivalent of a
ﬂuorophore, ±3%. In all of the experiments, the results were
consistent upon varying the host concentrations.28
The goal of our ﬁnal study was to explore the properties of
compound 8−DNA prism A as a diagnostic tool for antibody
detection in SLE. Compound 8 and prism A have been
selected on the basis of the high sensitivity to adding SLE sera
and superior quantum yield vs that of 5 (Supporting
Information, Table S1). We used a cohort obtained from
Odense University Hospital, Denmark, containing 80 adult
SLE and 60 healthy control (HC) samples. We benchmarked
the performance of compound 8−prism A to a commercial
ELISA assay. For this study, the patient samples were selected
on the basis of the diagnosed SLE and positivity to antinuclear
antibodies determined by a clinical lab. The median age of the
SLE-positive patients was 44.7 years and 84% were females.
For the experiments, patient sera were diluted 1:100 with
standard ELISA diluent. To achieve the required sensitivity
and speciﬁcity, the molar ratio 8/prism A was optimized for
the assay and kept at 250:1 (Supporting Information, Figure
S11A). Incubation with dye/dye−prism complex was carried
out at 37 °C for 1.5 h. Samples were analyzed by ﬂuorometry
using excitation of 370 nm (8) or 480 nm (Eva green).
We analyzed the position of ﬂuorescence maximum and
their intensities for compound 8−DNA prism complex in the
presence of human sera (Figure 4; Supporting Information,
Tables S6−S9). The mean wavelength for ﬂuorescence
maximum was 422 nm, which is 8 nm shorter compared to
the emission of the complex of compound 8−prism A in the
absence of serum. Minimum and maximum values for the
emission shift upon incubation were 0 and −12 nm,
respectively.
As for the intensity at emission maximum, 250 nM of
compound 8 in SLE sera had intensity of 18 ± 2 arb. units
(Supporting Information, Figure S7A). Upon adding 1 nM
prism A solution, the intensity increased to 69 ± 2 arb. units.
As in the preliminary assay, we observed quenching of
ﬂuorescence upon incubation of the compound 8−prism A
complex with SLE sera; mean intensity for these samples were
reduced to 43 ± 21 arb. units with a rather big deviation
among individual samples (Supporting Information, Table S8).
We observed a minimum intensity of 17 (quenching) and up
to 100 for some samples. Testing healthy controls (HC) gave a
cut-oﬀ value for the positivity by this assay, which was the
Figure 4. Box-and-whisker plots for the immunoﬂuorescence assay and ELISA. (a) Change in absorbance maximum upon incubation of the
complex 8−prism A with patient sera; (b) Change in ﬂuorescence intensity at maximum upon incubation of the complex 8−prism A with sera; (c)
Change in absorbance values determined by ELISA as a response to incubation with sera. The data is presented for SLE and healthy controls (HC;
number of patients: 80 (SLE) and 60 (HC)). The arms on each boxplot are values Q1 − 1.5 × interquartile range (IQR) and Q3 + 1.5 × IQR. Data
points for each measurement are mean values for two independent measurements with deviation of the results <3%.
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ﬂuorescence intensity change −8 units. In total, 32 SLE
samples were found to be positive by both wavelength shift and
quenching of ﬂuorescence intensity. However, only 32%
positive samples overlapped when the two types of positivity
were compared with each other. We carried out sandwich
ELISA for SLE samples (n = 80), as a control for the assay. In
this case, 46% were positive; only 45% of the positives
overlapped for the immunoﬂuorescence assay and ELISA.
Having tested healthy controls (n = 60), we observed a
somewhat similar performance of the ﬂuorescence assay using
the prism A/8 complex and the commercial ELISA kit (Figure
4, data for HC cohort). The total number of false positives by
ELISA was 6 (10%) vs 4 (7%) for our immunoﬂuorescence
assay.
To better understand the predictor role of the a-dsDNA
detected by compound 8−prism A, we performed correlation
analyses of the obtained antibody levels with clinical features of
the patients. The analysis was done for the immunoﬂuor-
escence and ELISA. Double positivity by emission intensity
and wavelength (n = 32) did correlate much stronger with
arthritis than the result provided by ELISA for these samples
(one-way ANOVA test; p = 3.3 × 10−5 compared to 0.68,
respectively; Supporting Information Table S11 and Figure
S12). We also observed a correlation of a-dsDNA levels
determined by the novel immunoﬂuorescence assay with
positivity to anti-β2-glycoprotein I antibodies (p = 0.014).
Our result can be further rationalized in terms of polyclonal
features of the antibodies. It is common that only 40−70% of
the SLE-positive subjects develop high level of a-dsDNA.3,6
Therefore, our results of ELISA lie within the expected range
of positivity (46%). It is also well documented that ELISA
reveals the broad range of antibodies. In turn, the compound
8−prism A complex in the ﬂuorescence assay might be more
speciﬁc to the antibodies with high aﬃnity.10 Eﬀective removal
of the dye molecules from the antigen, leading to an optical
eﬀect, requires high aﬃnity of the antibody to dsDNA which is
conﬁrmed by the low dissociation constant of prism A−
antibody complex in the presence of 8 (KD 0.24 nM). This is
also in agreement with the stronger correlation of the a-dsDNA
determined by compound 8−prism A with clinical features vs
ELISA. It is also worth mentioning that ELISA for a-dsDNA is
of IgG type only, whereas immunoﬂuorescence also detects
other antibody types (IgM, IgA). This could aﬀect the results
and correlations with clinical features as well. Lastly, it is
remarkable how the substitution in the organic ﬂuorophores
allows for the ﬁne tuning of its performance in sensing an
antibody. This makes us believe that merging organic synthesis
with emerging diagnostic needs could be a new paradigm for
assay development, which could positively aﬀect the research
and clinical management of diﬃcult conditions such as SLE.
3. CONCLUSIONS
In conclusion, in this study, we prepared and studied new
ﬂuorophores for the detection of human antibodies in serum.
In the homogeneous immunoﬂuorescence assay, novel DNA−
ﬂuorophore complexes show the required features of speciﬁcity
and sensitivity. This allowed us to screen 80 patient samples
diagnosed with an autoimmune disease, SLE, and to deﬁne
new clinical correlations for the determined antibody levels.
Further development of simple and reliable diagnostic
methods for human antibodies have a potential to open up
for new possibilities for using organic ﬂuorophores as eﬀective
diagnostic tools. In particular, we believe that this simple time-
and cost-eﬀective immunoﬂuorescence approach has much to
oﬀer to the rapidly developing ﬁeld of antibody analysis in
bioﬂuids.
4. EXPERIMENTAL SECTION
4.1. General. Synthesis and characterization of ﬂuoro-
phores 3−8 are described in Supporting Information.
All nucleic acid compounds were obtained from Integrated
DNA technologies, Inc., Iowa. Fluorescence dyes were
purchased from Sigma (TO) and Biotium (EG) and used as
received. Calf thymus DNA (CTD) was purchased from Sigma
(cat no. D1501).
4.2. Origami Sequences. These were designed and
prepared following published procedures.10,24−26 Annealing
procedures for origami and controls were carried out using 10
nM samples in 1× Tris-acetate-ethylenediaminetetraacetic acid
buﬀer with 12 mM MgCl2 as follows: lid 100 °C, 90 °C, 2 min,
90 → 60 decrease 0.5 °C per 1 min, 60 → 50 decrease 0.2 °C
per 10 min, 50 → 35 decrease 0.5 °C per 1 min; stored at
room temperature or 10 °C.
4.3. ELISA Assays. These were made manually following
the protocol described recently. Plates were analyzed using a
TECAN microplate reader and measuring absorbance at 450
nm. 96-well Maxisorb NUNC microplates were purchased
from Thermoﬁsher Scientiﬁc.
4.4. Monoclonal Antibody Controls. HYB 290-03 Anti-
β2-Microglobulin (human) clone 12B2 and HYB 331-01 anti-
double-stranded DNA clone 35I9 available from BioPorto
Diagnostics (Hellerup, Denmark) were generously provided by
Statens Serum Institute, Copenhagen.10
4.5. Patient Sera Samples and Healthy Controls.
These were obtained from Odense University Hospital,
Denmark. Control sera SLE1, SLE2, HCl, and HNP were
purchased from a commercial supplier (Immunovision).
4.6. General Protocol for Immunoﬂuorescence Assay.
In a microplate, DNA−ﬂuorophore antigen (4 μL, 10 nM
DNA, and 2.5 μM 8) was mixed with 4 μL freshly prepared
diluent (1 g BSA, 200 μL Tween-20 in 1 L 1× PBS).
Afterward, a 2 μL predilute serum sample was added (dilution
1:100 with 1 g BSA, 200 μL Tween-20 in 1 L 1× PBS).
Incubation was performed for 1.5 h at 37 °C, followed by
immediate ﬂuorescence detection at LightCycler 480 reader
(emission at 530 nm).
4.7. Data Analysis. Data analysis was performed in R using
one-way ANOVA.31
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